CA2136196A1 - 8-substituted anthines as phosphodiesterase inhibitors - Google Patents

8-substituted anthines as phosphodiesterase inhibitors

Info

Publication number
CA2136196A1
CA2136196A1 CA002136196A CA2136196A CA2136196A1 CA 2136196 A1 CA2136196 A1 CA 2136196A1 CA 002136196 A CA002136196 A CA 002136196A CA 2136196 A CA2136196 A CA 2136196A CA 2136196 A1 CA2136196 A1 CA 2136196A1
Authority
CA
Canada
Prior art keywords
compound
formula
group
pharmaceutically acceptable
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002136196A
Other languages
English (en)
French (fr)
Inventor
Ashley E. Fenwick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2136196A1 publication Critical patent/CA2136196A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002136196A 1992-05-21 1993-05-18 8-substituted anthines as phosphodiesterase inhibitors Abandoned CA2136196A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929210839A GB9210839D0 (en) 1992-05-21 1992-05-21 Novel compounds
GB9210839.8 1992-05-21

Publications (1)

Publication Number Publication Date
CA2136196A1 true CA2136196A1 (en) 1993-11-25

Family

ID=10715834

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002136196A Abandoned CA2136196A1 (en) 1992-05-21 1993-05-18 8-substituted anthines as phosphodiesterase inhibitors

Country Status (10)

Country Link
EP (1) EP0641344A1 (es)
JP (1) JPH07506591A (es)
CN (1) CN1094046A (es)
AU (1) AU4081493A (es)
CA (1) CA2136196A1 (es)
GB (1) GB9210839D0 (es)
MX (1) MX9302957A (es)
TW (1) TW277062B (es)
WO (1) WO1993023401A1 (es)
ZA (1) ZA933494B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
EP1043324B1 (en) 1997-11-12 2004-06-16 Mitsubishi Chemical Corporation Purine derivatives and medicine containing the same as the active ingredient
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
KR100747106B1 (ko) * 1999-05-11 2007-08-08 미쯔비시 가가꾸 가부시끼가이샤 퓨린 유도체 이수화물, 이를 유효성분으로 함유하는 의약및 이의 제조 중간체
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
NZ517546A (en) * 1999-08-31 2003-10-31 Univ Vanderbilt Selective antagonists of A2B adenosine receptors
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
WO2001062979A2 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Dentification of partial agonists of the a2a adenosine receptor
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
EP1421084B1 (en) 2001-08-28 2008-05-14 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
US6943171B2 (en) 2001-11-09 2005-09-13 Schering Corporation Polycyclic guanine derivative phosphodiesterase V inhibitors
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
US7495004B2 (en) 2002-06-17 2009-02-24 Glaxo Group Limited Purine derivatives as liver X receptor agonists
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
CA2492855C (en) 2002-07-29 2012-09-18 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US20050020915A1 (en) 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
DE602004006756T2 (de) * 2003-07-31 2008-01-24 Schering Corp. Metabolite eines xanthinphosphodiesterase-5-inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen
EP1802317A2 (en) 2004-10-20 2007-07-04 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists
AU2007212542B2 (en) 2006-02-03 2013-01-31 Gilead Sciences, Inc. Process for preparing an A2A-Adenosine receptor agonist and its polymorphs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779374D1 (en) * 1986-08-28 1992-07-02 Sandoz Ag Xanthinderivate.
IT1229195B (it) * 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
ES2148170T3 (es) * 1990-12-21 2000-10-16 Beecham Group Plc Derivados de xantina.

Also Published As

Publication number Publication date
WO1993023401A1 (en) 1993-11-25
EP0641344A1 (en) 1995-03-08
MX9302957A (es) 1994-05-31
AU4081493A (en) 1993-12-13
CN1094046A (zh) 1994-10-26
GB9210839D0 (en) 1992-07-08
ZA933494B (en) 1994-03-01
JPH07506591A (ja) 1995-07-20
TW277062B (es) 1996-06-01

Similar Documents

Publication Publication Date Title
CA2136196A1 (en) 8-substituted anthines as phosphodiesterase inhibitors
CA2112239C (en) Enantiomeric hydroxylated xanthine compounds
US5409934A (en) Xanthine derivatives
US5981535A (en) Substituted xanthines and their use in the treatment of cerebrovascular disorders and other diseases
US5919789A (en) Xanthines and their therapeutic use
AU653364B2 (en) Xanthine derivatives
JP3131225B2 (ja) Ｎ−（アロイル）グリシンヒドロキサム酸誘導体および関連化合物
EP0623133B1 (en) Substituted amino alkyl compounds
JPH02501829A (ja) インターロイキン‐１の活性を抑制する方法
AU650679B2 (en) Xanthines
US6440979B1 (en) Aryl isoguanines
US6248746B1 (en) 3-(arylalkyl) xanthines
US6693105B1 (en) Hydroxyl-containing compounds

Legal Events

Date Code Title Description
FZDE Dead